Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 23,002 shares at $22.08 ($509K) on 2025-06-17, disclosed to the SEC on 2025-06-18.
Scheduled sale ($509k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.08 | 10,502 | $232K | 45.5% |
| 2 | $22.08 | 10,502 | $232K | 45.5% |
| 3 | $22.75 | 1,998 | $45K | 8.9% |
| Total | $22.14 avg | 23,002 | $509K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |